SG11201407890VA - Tetrahydropyrazolopyrimidine compounds - Google Patents

Tetrahydropyrazolopyrimidine compounds

Info

Publication number
SG11201407890VA
SG11201407890VA SG11201407890VA SG11201407890VA SG11201407890VA SG 11201407890V A SG11201407890V A SG 11201407890VA SG 11201407890V A SG11201407890V A SG 11201407890VA SG 11201407890V A SG11201407890V A SG 11201407890VA SG 11201407890V A SG11201407890V A SG 11201407890VA
Authority
SG
Singapore
Prior art keywords
massachusetts
international
road
avenue
publication
Prior art date
Application number
SG11201407890VA
Inventor
Lynn D Hawkins
Roch Boivin
Eric Carlson
Atsushi Endo
Hans Hansen
Sally Ishizaka
Matthew Mackey
Sridhar Narayan
Takashi Satoh
Shawn Schiller
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of SG11201407890VA publication Critical patent/SG11201407890VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 5 December 2013 (05.12.2013) WIPOIPCT (10) International Publication Number WO 2013/181579 A3 (51) International Patent Classification: C07D 471/04 (2006.01) A61P 37/00 (2006.01) A61K31/519 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 61/654,023 31 May 2012 (31.05.2012) (74) Agents: WALTERS, Todd R. et al.; Buchanan Ingersoll & Rooney PC, (customer no. 21839), P.O. Box 1404, Al­ exandria, Virginia 22313-1404 (US). PCT/US2013/043679 31 May 2013 (31.05.2013) English (71) Applicant: EISAI R&D MANAGEMENT CO., LTD. [JP/JP]; 6-10, Koishikawa 4-Chome, Bunkyo-ku, Tokyo 112-8088 (JP). (72) Inventor; and (71) Applicant (for US only): HAWKINS, Lynn D. [US/US]; 963 Lowell Road, Concord, Massachusetts 01742 (US). (72) Inventors: BOIVIN, Roch; 18 Strawberry Hill road, North Chelmsford, Massachusetts 01863 (US). CARLSON, Eric; 14 Blair Road, Merrimack, New Hampshire 03054 (US). ENDO, Atsushi; Apt. 1123, 311 Lowell Street, An- dover, Massachusetts 01810 (US). HANSEN, Hans; Apt. 3, 18 Sanborn Avenue, Somerville, Massachusetts 02143 (US). ISHIZAKA, Sally; 110 Mountvale Road, Weston, Massachusetts 02493 (US). MACKEY, Matthew; 52 Henry Avenue, Melrose, Massachusetts 02176 (US). NARAYAN, Sridhar; 22 Thomas Street, Belmont, Mas­ sachusetts 02478 (US). SATOH, Takashi; 21 Paulornette Circle, Andover, Massachusetts 01810 (US). SCHILLER, Shawn; 614 Hilldale Avenue, Haverhill, Massachusetts 01832 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, us SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) (88) Date of publication of the international search report: 27 March 2014 o\ i> •H 00 i-H o CJ (54) Title: TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS (57) Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibit­ ors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus eryth­ ematosus (SLE) and lupus nephritis
SG11201407890VA 2012-05-31 2013-05-31 Tetrahydropyrazolopyrimidine compounds SG11201407890VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261654023P 2012-05-31 2012-05-31
PCT/US2013/043679 WO2013181579A2 (en) 2012-05-31 2013-05-31 Tetrahydropyrazolopyrimidine compounds

Publications (1)

Publication Number Publication Date
SG11201407890VA true SG11201407890VA (en) 2014-12-30

Family

ID=48626649

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407890VA SG11201407890VA (en) 2012-05-31 2013-05-31 Tetrahydropyrazolopyrimidine compounds

Country Status (34)

Country Link
US (5) US9126999B2 (en)
EP (1) EP2855476B1 (en)
JP (2) JP6285918B2 (en)
KR (2) KR102403007B1 (en)
CN (2) CN104507939B (en)
AR (1) AR091236A1 (en)
AU (2) AU2013267204B8 (en)
BR (1) BR112014030060B1 (en)
CA (1) CA2874445C (en)
CL (1) CL2014003278A1 (en)
CY (1) CY1122692T1 (en)
DK (1) DK2855476T3 (en)
ES (1) ES2709119T3 (en)
HK (1) HK1203498A1 (en)
HR (1) HRP20181889T1 (en)
HU (1) HUE040562T2 (en)
IL (2) IL268013B2 (en)
JO (1) JO3407B1 (en)
LT (1) LT2855476T (en)
MX (1) MX368455B (en)
MY (1) MY172926A (en)
NZ (1) NZ703459A (en)
PE (2) PE20190973A1 (en)
PH (2) PH12014502660A1 (en)
PL (1) PL2855476T3 (en)
PT (1) PT2855476T (en)
RS (1) RS57977B1 (en)
RU (2) RU2733959C2 (en)
SG (1) SG11201407890VA (en)
SI (1) SI2855476T1 (en)
TW (1) TWI572606B (en)
UA (1) UA113440C2 (en)
WO (1) WO2013181579A2 (en)
ZA (1) ZA201409273B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3407B1 (en) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd Tetrahydropyrazolopyrimidine Compounds
TWI652014B (en) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 Heterocyclic substituted bicycloazole insecticide
CN107935988A (en) 2013-10-14 2018-04-20 卫材R&D管理有限公司 The quinoline compound selectively substituted
TWI702218B (en) 2013-10-14 2020-08-21 日商衛材R&D企管股份有限公司 Selectively substituted quinoline compounds
JP2016540013A (en) * 2013-12-13 2016-12-22 武田薬品工業株式会社 Pyrrolo [3,2-C] pyridine derivatives as TLR inhibitors
MX367913B (en) * 2014-03-27 2019-09-11 Janssen Pharmaceutica Nv SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZ OLE DERIVATIVES AS ROS1 INHIBITORS.
DK3174858T3 (en) 2014-07-31 2019-07-15 Basf Se PROCEDURE FOR THE PREPARATION OF PYRAZOLS
US9938100B2 (en) 2014-12-30 2018-04-10 Kodak Alaris Inc. System and method for metallic object detection in a media transport system
EP3294725B1 (en) 2015-05-11 2021-05-05 Basf Se Process for preparing 4-amino-pyridazines
WO2017004734A1 (en) * 2015-07-03 2017-01-12 中国农业大学 Benzyl hydrazone compound, and preparation method and use thereof
US10975036B2 (en) * 2016-02-02 2021-04-13 Basf Se Catalytic hydrogenation process for preparing pyrazoles
CN107174585A (en) * 2016-03-10 2017-09-19 兰州大学 It can be used as the new application of the pyridine-imidazole class compound of androgen receptor antagonists
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
SG11201900619XA (en) * 2016-07-30 2019-02-27 Bristol Myers Squibb Co Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
CN109790126A (en) * 2016-08-02 2019-05-21 索尔维公司 Manufacture, hydrazo compound and application thereof for manufacturing the hydrazo compound of pyrazole carboxylic acid and derivative
KR102519535B1 (en) * 2016-09-09 2023-04-06 브리스톨-마이어스 스큅 컴퍼니 Pyridyl substituted indole compounds
RS62913B1 (en) * 2016-09-09 2022-03-31 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
TW201900647A (en) * 2017-05-18 2019-01-01 大陸商江蘇恒瑞醫藥股份有限公司 Heteroarylpyrazole derivatives, preparation method thereof and application thereof in medicine
ES2909401T3 (en) 2017-08-04 2022-05-06 Bristol Myers Squibb Co Substituted Indole Compounds Useful as Inhibitors of TLR7/8/9
CN110997670B (en) 2017-08-04 2022-11-01 百时美施贵宝公司 [1,2,4] triazolo [4,3-a ] pyridyl substituted indole compounds
EP3710440B1 (en) 2017-11-14 2023-04-05 Bristol-Myers Squibb Company Substituted indole compounds
KR102037494B1 (en) 2017-12-11 2019-10-28 씨제이헬스케어 주식회사 Intermediates of chiral piperidine derivatives and preparation method thereof
WO2019118799A1 (en) * 2017-12-15 2019-06-20 Bristol-Myers Squibb Company Substituted indole ether compounds
KR20200100709A (en) 2017-12-18 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 4-azaindole compound
BR112020012084A2 (en) * 2017-12-19 2020-11-24 Bristol-Myers Squibb Company substituted indole compounds useful as tlr inhibitors
ES2922174T3 (en) * 2017-12-19 2022-09-09 Bristol Myers Squibb Co Amide Substituted Indole Compounds Useful as TLR Inhibitors
WO2019126082A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company 6-azaindole compounds
WO2019126242A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Amino indole compounds useful as tlr inhibitors
EP3728188B1 (en) 2017-12-20 2023-10-11 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds
MX2020006014A (en) 2017-12-20 2020-08-17 Bristol Myers Squibb Co Diazaindole compounds.
KR20200103741A (en) * 2017-12-22 2020-09-02 솔베이(소시에떼아노님) Method for preparing pyrazole carboxylic acid derivative and precursor thereof
WO2019123294A2 (en) 2017-12-22 2019-06-27 Novartis Ag Novel uses of pyrazolo piperidine derivatives
WO2019235553A1 (en) * 2018-06-07 2019-12-12 第一三共株式会社 Azetidine derivative, and prodrug thereof
EP3847173B1 (en) * 2018-09-06 2023-04-12 F. Hoffmann-La Roche AG Novel pyrazolopyridine compounds for the treatment of autoimmune disease
JP2022505827A (en) 2018-10-24 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー Substituted indole dimer compound
EP3877388B1 (en) * 2018-11-09 2023-07-26 F. Hoffmann-La Roche AG 5-[6-[[3-(4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl)azetidin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile derivatives and similar compounds as tlr7-9 antagonists for treating systemic lupus erythematosus
KR20210125026A (en) * 2019-02-07 2021-10-15 베이진 엘티디 Imidazo[2,1-F][1,2,4]triazin-4-amine derivatives as TLR7 agonists
EP4008720A4 (en) * 2019-08-02 2023-08-02 BeiGene, Ltd. Imidazo[2,1-f][1,2,4]triazin-4-amine derivative used as tlr8 agonist
KR20190120112A (en) 2019-10-08 2019-10-23 씨제이헬스케어 주식회사 Intermediates of chiral piperidine derivatives and preparation method thereof
EP4082611A4 (en) * 2019-12-06 2023-12-27 Daiichi Sankyo Company, Limited Azetidine sulfonamide compound
CA3214808A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Thienopyrrole compounds

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3116230B2 (en) 1989-02-15 2000-12-11 武田薬品工業株式会社 Tricyclic fused pyrimidine derivatives
JPH04133055A (en) 1990-09-25 1992-05-07 Konica Corp Silver halide color photographic sensitive material improved in color reproducibility
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
FR2733749B1 (en) 1995-05-05 1997-06-13 Oreal COMPOSITIONS FOR DYEING KERATINIC FIBERS CONTAINING DIAMINO PYRAZOLES, DYEING PROCESS, NOVEL DIAMINO PYRAZOLES, AND PREPARATION METHOD THEREOF
DE19709877A1 (en) 1997-03-11 1998-09-17 Bayer Ag 1,5-dihydro-pyrazolo [3,4-d] pyrimidinone derivatives
US6472416B1 (en) 1999-08-27 2002-10-29 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors
UA72611C2 (en) 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Derivatives of substituted pyrrolopyridinone useful as phosphodiesterase inhibitors
CZ20031554A3 (en) 2000-12-06 2003-08-13 Aventis Pharma Deutschland Gmbh Guanidine and amidine derivatives functioning as XA factor inhibitors
AU2002302419B2 (en) * 2001-03-14 2007-01-18 Grunenthal Gmbh Substituted Pyrazolopyrimidines and thiazolopyrimidines used as analgesics
ES2247527T3 (en) 2002-04-26 2006-03-01 Pfizer Prod Inc METALOPROTEINASE TRIARIL-OXI-ARIL-ESPIRO-PYRIMIDINE-2,4,6-TRIONA INHIBITORS.
DE10221100C1 (en) 2002-05-03 2003-06-05 Neuhaus Elektronik Gmbh Electrically conducting seal, consists of an elastically hardenable material that contains magnetic particles, which is extruded onto a surface and then subjected to a magnetic field
JP2003327860A (en) 2002-05-09 2003-11-19 Konica Minolta Holdings Inc Colored composition, colored microparticle dispersion, ink for ink jet and method for ink jet recording
PT1534707E (en) 2002-06-19 2007-12-19 Janssen Pharmaceutica Nv Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
JP4133055B2 (en) 2002-07-11 2008-08-13 株式会社イトーキ Automated warehouse with transfer mechanism
CN1771231B (en) * 2002-08-26 2011-05-25 武田药品工业株式会社 Calcium receptor modulating compound and use thereof
CA2494700C (en) 2002-08-26 2011-06-28 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
AU2003274652A1 (en) 2002-10-23 2004-05-13 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
SE0300120D0 (en) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
WO2004089415A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
JP2006525357A (en) 2003-04-30 2006-11-09 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー Substituted heteroaryls as protein tyrosine phosphatase inhibitors
WO2004099192A2 (en) 2003-04-30 2004-11-18 The Institutes Of Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
CA2527582A1 (en) 2003-06-12 2004-12-23 Merck & Co., Inc. Prodrugs of mitotic kinesin inhibitors
WO2005002555A2 (en) 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
FR2865208B1 (en) 2004-01-16 2009-01-16 Sanofi Synthelabo 1,4-DIAZABICYCLO [3.2.1] OCTANECARBOXMIQUE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
US7279232B2 (en) 2004-01-26 2007-10-09 Universal Display Corporation Electroluminescent stability
WO2005087765A1 (en) 2004-03-04 2005-09-22 Arena Pharmaceuticals, Inc. Ligands of follicle stimulating hormone receptor and methods of use thereof
US7825265B2 (en) 2004-05-04 2010-11-02 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptors
ZA200609870B (en) 2004-05-04 2009-12-30 Acadia Pharm Inc Compounds with activity at estrogen receptor
AU2005295902A1 (en) 2004-10-12 2006-04-27 Decode Genetics Ehf Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease
JP2008520692A (en) 2004-11-18 2008-06-19 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー Heterocyclic substituted carboxylic acids
US20080051418A1 (en) 2004-11-26 2008-02-28 Tsuyoshi Maekawa Arylalkanoic Acid Derivative
CA2595486A1 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
WO2006105440A2 (en) 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
EP1905762A1 (en) 2005-05-30 2008-04-02 Genecare Research Institute Co., Ltd Pyrazolone derivative
JPWO2006129587A1 (en) 2005-05-30 2009-01-08 株式会社ジーンケア研究所 Pharmaceutical composition containing pyrazolone derivative
WO2006133216A2 (en) 2005-06-06 2006-12-14 Smithkline Beecham Corporation 4-substituted arylamine derivatives and their use in pharmaceutical compositions
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
JP5066516B2 (en) 2005-09-01 2012-11-07 アステラス製薬株式会社 Pyridazinone derivatives used for the treatment of pain
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
US7915305B2 (en) 2006-01-23 2011-03-29 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
EP1992348A4 (en) 2006-03-08 2009-09-23 Takeda Pharmaceutical Pharmaceutical combination
WO2007125320A1 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
US7851495B2 (en) 2006-05-23 2010-12-14 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
WO2007139816A2 (en) 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
BRPI0712332A2 (en) 2006-06-09 2012-12-18 Icos Corp pharmaceutically acceptable compound and derivatives thereof, pharmaceutical composition, method of antagonizing a dp-2 receptor, and use of a compound
BRPI0714409A2 (en) 2006-07-14 2013-03-12 Novartis Ag pyrimidine derivatives as alk-5 inhibitors
US7985753B2 (en) 2006-08-04 2011-07-26 Merz Pharma Gmbh & Co. Kgaa Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators
WO2008033894A2 (en) 2006-09-14 2008-03-20 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptors
EP2099454A4 (en) 2006-11-17 2010-11-10 Abbott Lab Aminopyrrolidines as chemokine receptor antagonists
PE20081581A1 (en) 2006-12-21 2008-11-12 Plexxikon Inc PIRROLO [2,3-b] PYRIDINES COMPOUNDS AS KINASE MODULATORS
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP2010518014A (en) 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド 2-Aminopyridine derivatives useful as kinase inhibitors
JP2010518080A (en) 2007-02-08 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション Remedy
EP2009002A1 (en) 2007-06-21 2008-12-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) New process for the manufacture of 1H-imidazo [4,5-c]-quinoline ring systems
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
US8022209B2 (en) 2007-09-12 2011-09-20 Janssen Pharmaceutica Nv Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
EP2220087A1 (en) * 2007-11-15 2010-08-25 Eisai R&D Management Co., Ltd. Enantiomerically enriched imidazoazepinone compounds
KR20100102646A (en) * 2007-12-11 2010-09-24 가부시키가이샤 사이토파스파인더 Carboxamide compounds and their use as chemokine receptor agonists
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester Method for altering the lifespan of eukaryotic organisms
PL2231642T3 (en) 2008-01-11 2014-04-30 Novartis Ag Pyrimidines as kinase inhibitors
AR070127A1 (en) 2008-01-11 2010-03-17 Novartis Ag PIRROLO - PIRIMIDINAS AND PIRROLO -PIRIDINAS
US8338392B2 (en) 2008-02-20 2012-12-25 The Wistar Institute MicroRNA modulators and method for identifying and using the same
US20120010177A1 (en) 2008-02-20 2012-01-12 The Wistar Institute / North Carolina State University MicroRNA Modulators and Method for Identifying And Using The Same
WO2009111207A1 (en) 2008-03-04 2009-09-11 Merck & Co., Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
US9066951B2 (en) 2008-05-29 2015-06-30 Wisconsin Alumni Research Foundation Drugs to treat HPV infection
WO2009151991A1 (en) 2008-06-11 2009-12-17 Merck & Co., Inc. Pyrazole derivatives useful as inhibitors of faah
EP2300438A4 (en) 2008-06-11 2012-06-27 Merck Sharp & Dohme Imidazole derivatives useful as inhibitors of faah
US20110306597A1 (en) 2008-06-18 2011-12-15 James Michael Crawforth Nicotinamide Derivatives
EP2307377A1 (en) 2008-06-18 2011-04-13 Pfizer Limited Nicotinamide derivatives
WO2009158396A1 (en) 2008-06-25 2009-12-30 Bristol-Myers Squibb Company Diketopiperidine derivatives as hiv attachment inhibitors
US8263642B2 (en) 2008-06-25 2012-09-11 Vanderbilt University Antimicrobial compounds and methods of use thereof
US7960406B2 (en) 2008-06-25 2011-06-14 Bristol-Myers Squibb Company Diketo substituted pyrrolo[2,3-c] pyridines
UY31952A (en) 2008-07-02 2010-01-29 Astrazeneca Ab 5-METHYLIDENE-1,3-THIAZOLIDINE-2,4-DIONAS REPLACED AS PIM QUINASE INHIBITORS
NZ590747A (en) 2008-07-28 2012-11-30 Gilead Sciences Inc Cycloalkylidene and heterocycloalkylidene hdac inhibitor compounds
CA2732526A1 (en) 2008-08-04 2010-02-11 Merck Sharp & Dohme Corp. Oxazole derivatives useful as inhibitors of faah
US20110251172A1 (en) 2008-08-13 2011-10-13 Rivkin Alexey A Purine derivatives for treatment of alzheimer's disease
US8507491B2 (en) 2008-08-25 2013-08-13 Irm Llc Compounds and compositions as hedgehog pathway inhibitors
JP2012503623A (en) 2008-09-24 2012-02-09 ビーエーエスエフ ソシエタス・ヨーロピア Pyrazole compounds for invertebrate pest control
WO2010096115A1 (en) * 2008-10-29 2010-08-26 Apath, Llc Compounds, compositions and methods for control of hepatitis c viral infections
JP2012508250A (en) 2008-11-07 2012-04-05 ワイス・エルエルシー Quinoxaline-based LXR modulator
KR20110110183A (en) 2009-01-19 2011-10-06 다이이찌 산쿄 가부시키가이샤 Cyclic compound having hetero atom
WO2010083199A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
ES2761295T3 (en) 2009-03-02 2020-05-19 Stemsynergy Therapeutics Inc Methods and compositions for use in cancer treatment and to reduce Wnt-mediated effects in a cell
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US20120141483A1 (en) 2009-06-04 2012-06-07 Mary Katherine Delmedico Methods of treating or preventing psoriasis, and/or alzheimer's disease using indane acetic acid derivatives
US20110021531A1 (en) 2009-07-27 2011-01-27 Chobanian Harry Oxazole derivatives useful as inhibitors of faah
EP2470183B1 (en) 2009-08-26 2015-09-16 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
EP2501696B1 (en) 2009-10-15 2016-12-28 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
TWI531571B (en) 2009-11-06 2016-05-01 維它藥物公司 Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
JP2013032290A (en) * 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd Novel fused pyrimidine derivative
WO2011072064A1 (en) 2009-12-08 2011-06-16 Array Biopharma Inc. S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors
FR2953837B1 (en) 2009-12-10 2012-03-09 Sanofi Aventis DISUBSTITUTED 9H-PYRIDINO [3,4-B] INDOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
WO2011079000A1 (en) 2009-12-22 2011-06-30 Schering Corporation DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b]PURIN-4(5H)-ONE AND METHODS OF USE THEREOF
EP2523664A4 (en) 2010-01-13 2013-06-26 Tempero Pharmaceuticals Inc Compounds and methods
RU2012136624A (en) 2010-01-28 2014-03-10 Мерк Шарп Энд Домэ Корп. PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN AND OTHER INDICATIONS
US20110190266A1 (en) 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
EP2552905B1 (en) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH B-Raf kinase inhibitors
JP5871897B2 (en) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyridyltriazole
EP2371219A1 (en) 2010-04-01 2011-10-05 Basf Se Herbicidal acylhydrazides
CA2914966A1 (en) 2010-04-05 2011-10-13 Mannkind Corporation Ire-1alpha inhibitors
US9073879B2 (en) 2010-04-22 2015-07-07 Merck Sharp & Dohme Corp. Oxazole derivatives useful as modulators of FAAH
WO2011133727A2 (en) 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
EP2401915A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
CN102048738A (en) 2010-12-08 2011-05-11 辽宁利锋科技开发有限公司 Medicament combination preparation of medicinal compound containing cy-ethyl razepam
UA117902C2 (en) 2011-07-29 2018-10-25 Каріофарм Терапеутікс, Інк. Nuclear transport modulators and uses thereof
CN106083827B (en) 2011-07-29 2019-09-17 卡尔约药物治疗公司 Core transport regulator containing hydrazides and application thereof
JP2013159564A (en) * 2012-02-02 2013-08-19 Kowa Co Tlr9 inhibitor including pyrazolopyrimidine-7-amine derivative as active ingredient
SI2814829T1 (en) 2012-02-13 2017-02-28 Bristol-Myers Squibb Company Enediyne compounds, conjugates thereof, and uses and methods therefor
JO3407B1 (en) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd Tetrahydropyrazolopyrimidine Compounds
SG11201407919WA (en) 2012-05-31 2014-12-30 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]

Also Published As

Publication number Publication date
AR091236A1 (en) 2015-01-21
PE20150220A1 (en) 2015-02-14
PH12014502660B1 (en) 2015-01-21
JO3407B1 (en) 2019-10-20
JP2018087221A (en) 2018-06-07
CN104507939B (en) 2017-07-25
RU2018146532A (en) 2019-01-31
PE20190973A1 (en) 2019-07-09
WO2013181579A2 (en) 2013-12-05
CA2874445A1 (en) 2013-12-05
PH12014502660A1 (en) 2015-01-21
RU2018146532A3 (en) 2019-06-21
TW201402575A (en) 2014-01-16
KR102268155B1 (en) 2021-06-24
BR112014030060B1 (en) 2022-05-31
US20160030430A1 (en) 2016-02-04
RU2014154397A (en) 2016-07-27
KR102403007B1 (en) 2022-05-31
US20200347050A1 (en) 2020-11-05
SI2855476T1 (en) 2018-12-31
KR20150016366A (en) 2015-02-11
ES2709119T3 (en) 2019-04-15
PH12019500522A1 (en) 2020-11-04
AU2013267204A8 (en) 2017-04-13
EP2855476B1 (en) 2018-09-05
CY1122692T1 (en) 2020-07-31
MX2014014497A (en) 2015-06-02
US20130324547A1 (en) 2013-12-05
HRP20181889T1 (en) 2019-01-11
WO2013181579A3 (en) 2014-03-27
RS57977B1 (en) 2019-01-31
HUE040562T2 (en) 2019-03-28
PT2855476T (en) 2018-12-03
PL2855476T3 (en) 2019-02-28
JP2015523981A (en) 2015-08-20
US9446046B2 (en) 2016-09-20
MX368455B (en) 2019-10-03
KR20210076210A (en) 2021-06-23
CA2874445C (en) 2022-06-21
TWI572606B (en) 2017-03-01
NZ703459A (en) 2016-09-30
RU2677291C2 (en) 2019-01-16
IL268013A (en) 2019-09-26
IL268013B2 (en) 2024-05-01
CN107344941A (en) 2017-11-14
AU2013267204B2 (en) 2017-04-06
AU2017204586B2 (en) 2018-11-08
ZA201409273B (en) 2016-05-25
MY172926A (en) 2019-12-14
UA113440C2 (en) 2017-01-25
US11130758B2 (en) 2021-09-28
US20180273532A1 (en) 2018-09-27
EP2855476A2 (en) 2015-04-08
HK1203498A1 (en) 2015-10-30
BR112014030060A2 (en) 2017-09-12
CN104507939A (en) 2015-04-08
AU2013267204A1 (en) 2015-01-29
IL235986B (en) 2019-11-28
US9850242B2 (en) 2017-12-26
DK2855476T3 (en) 2018-12-17
CL2014003278A1 (en) 2015-06-12
AU2013267204B8 (en) 2017-04-13
CN107344941B (en) 2020-04-21
US20160339032A1 (en) 2016-11-24
LT2855476T (en) 2019-01-10
IL268013B1 (en) 2024-01-01
US9126999B2 (en) 2015-09-08
JP6285918B2 (en) 2018-02-28
IL235986A0 (en) 2015-02-01
RU2733959C2 (en) 2020-10-08
US10640500B2 (en) 2020-05-05
JP6619829B2 (en) 2019-12-11
AU2017204586A1 (en) 2017-07-27

Similar Documents

Publication Publication Date Title
SG11201407890VA (en) Tetrahydropyrazolopyrimidine compounds
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201407268SA (en) Nuclear transport modulators and uses thereof
SG11201808990QA (en) Compositions for topical application of compounds
SG11201408261UA (en) Syringe
SG11201907496RA (en) Cyclic di-nucleotides compounds for the treatment of cancer
SG11201806624XA (en) Deposition of molybdenum thin films using a molybdenum carbonyl precursor
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201407662WA (en) Process for the preparation of treprostinil and derivatives thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201407200TA (en) Liquid formulation
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201900745VA (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
SG11201407793TA (en) Compounds and compositions for modulating egfr activity
SG11201806583XA (en) Compositions containing tucaresol or its analogs
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201407775WA (en) Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
SG11201803834UA (en) Methods for treating conditions associated with masp-2 dependent complement activation
SG11201406973PA (en) Complement pathway modulators and uses thereof
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones